CGEN Earnings

CGEN reported its earnings on 2026-03-02, showcasing a revenue of 67.33M against an estimate of 17.87M, resulting in a 276.79% surprise. The EPS was 0.6, surpassing the expected 0.05 by 1100%. The stock experienced a 24.31% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CGEN's earnings announcement on 2026-03-02, the stock price moved by 24.31% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CGEN's stock price tends to shift by an average of 6.06% in the 10 days leading up to earnings and 3.9% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CGEN's annual revenue to reach 1.25M, while the EPS is projected at -0.08. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CGEN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CGEN's stock price typically moves by 6.06% in the 10 days before its earnings and 3.9% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.08 and revenue of 1.25M.

The earnings call reveals strong financial performance, with significant revenue growth and a net profit turnaround due to strategic partnerships with AstraZeneca and Gilead. The cash runway supports ongoing projects, and milestone payments are lined up. Despite some uncertainties in timelines, the strategic partnerships and potential in the oncology field are promising. Analysts' questions highlight interest in future milestones and expansions, suggesting confidence in the company's direction. The positive financial results and strategic developments suggest a positive impact on stock price.